NASDAQ:CLSNCelsion Stock Price, Forecast & News

Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLSN shares have increased by 15.2% and is now trading at $1.14.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Celsion.

Celsion is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) announced its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.03. The biotechnology company earned $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 3,908.00% and a negative return on equity of 120.14%.
View Celsion's earnings history.

Shares of Celsion reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

2 analysts have issued twelve-month price objectives for Celsion's shares. Their forecasts range from $4.00 to $4.00. On average, they expect Celsion's stock price to reach $4.00 in the next year. This suggests a possible upside of 250.9% from the stock's current price.
View analysts' price targets for Celsion.

Media coverage about CLSN stock has trended neutral on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Celsion earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Celsion.

Some companies that are related to Celsion include Evofem Biosciences (EVFM), Tonix Pharmaceuticals (TNXP), Minerva Neurosciences (NERV), Kindred Biosciences (KIN), CELYAD SA/ADR (CYAD), Harrow Health (HROW), Mustang Bio (MBIO), Eton Pharmaceuticals (ETON), Genprex (GNPX), OASMIA PHARMACE/ADR (OASM), Galectin Therapeutics (GALT), KITOV PHARMA LT/S (KTOV), ESSA Pharma (EPIX), Checkpoint Therapeutics (CKPT) and Obseva (OBSV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Amarin (AMRN), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), NovaBay Pharmaceuticals (NBY), Novavax (NVAX) and Gilead Sciences (GILD).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.08%), Park Avenue Securities LLC (0.08%) and Total Investment Management Inc. (0.08%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper.
View institutional ownership trends for Celsion.

CLSN stock was purchased by a variety of institutional investors in the last quarter, including Park Avenue Securities LLC, Envestnet Asset Management Inc., and Total Investment Management Inc.. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno, and Robert W Hooper.
View insider buying and selling activity for Celsion.

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $1.14.

Celsion has a market capitalization of $37.88 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

The official website for Celsion is www.celsion.com.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]